Open Access

Establishment and characterization of prostate organoids from treatment‑naïve patients with prostate cancer

  • Authors:
    • Katia Cheaito
    • Hisham F. Bahmad
    • Ola Hadadeh
    • Hiba Msheik
    • Alissar Monzer
    • Farah Ballout
    • Christelle Dagher
    • Talar Telvizian
    • Nour Saheb
    • Ayman Tawil
    • Marwan El‑Sabban
    • Albert El‑Hajj
    • Deborah Mukherji
    • Mohamed Al‑Sayegh
    • Wassim Abou‑Kheir
  • View Affiliations

  • Published online on: November 5, 2021     https://doi.org/10.3892/ol.2021.13124
  • Article Number: 6
  • Copyright: © Cheaito et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Three‑dimensional (3D) organoid culture systems are emerging as potential reliable tools to investigate basic developmental processes of human disease, especially cancer. The present study used established and modified culture conditions to report successful generation and characterization of patient‑derived organoids from fresh primary tissue specimens of patients with treatment‑naïve prostate cancer (PCa). Fresh tissue specimens were collected, digested enzymatically and the resulting cell suspensions were plated in a 3D environment using Matrigel as an extracellular matrix. Previously established 12‑factor medium for organoid culturing was modified to create a minimal 5‑factor medium. Organoids and corresponding tissue specimens were characterized using transcriptomic analysis, immunofluorescent analysis, and immunohistochemistry. Furthermore, patient‑derived organoids were used to assess the drug response. Treatment‑naïve patient‑derived PCa organoids were obtained from fresh radical prostatectomy specimens. These PCa organoids mimicked the heterogeneity of corresponding parental tumor tissue. Histopathological analysis demonstrated similar tissue architecture and cellular morphology, as well as consistent immunohistochemical marker expression. Also, the results confirmed the potential of organoids as an in vitro model to assess potential personalized treatment responses as there was a differential drug response between different patient samples. In conclusion, the present study investigated patient‑derived organoids from a cohort of treatment‑naïve patients. Derived organoids mimicked the histological features and prostate lineage profiles of their corresponding parental tissue and may present a potential model to predict patient‑specific treatment response in a pre‑clinical setting.
View References

Related Articles

Journal Cover

January-2022
Volume 23 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Cheaito K, Bahmad HF, Hadadeh O, Msheik H, Monzer A, Ballout F, Dagher C, Telvizian T, Saheb N, Tawil A, Tawil A, et al: Establishment and characterization of prostate organoids from treatment‑naïve patients with prostate cancer. Oncol Lett 23: 6, 2022.
APA
Cheaito, K., Bahmad, H.F., Hadadeh, O., Msheik, H., Monzer, A., Ballout, F. ... Abou‑Kheir, W. (2022). Establishment and characterization of prostate organoids from treatment‑naïve patients with prostate cancer. Oncology Letters, 23, 6. https://doi.org/10.3892/ol.2021.13124
MLA
Cheaito, K., Bahmad, H. F., Hadadeh, O., Msheik, H., Monzer, A., Ballout, F., Dagher, C., Telvizian, T., Saheb, N., Tawil, A., El‑Sabban, M., El‑Hajj, A., Mukherji, D., Al‑Sayegh, M., Abou‑Kheir, W."Establishment and characterization of prostate organoids from treatment‑naïve patients with prostate cancer". Oncology Letters 23.1 (2022): 6.
Chicago
Cheaito, K., Bahmad, H. F., Hadadeh, O., Msheik, H., Monzer, A., Ballout, F., Dagher, C., Telvizian, T., Saheb, N., Tawil, A., El‑Sabban, M., El‑Hajj, A., Mukherji, D., Al‑Sayegh, M., Abou‑Kheir, W."Establishment and characterization of prostate organoids from treatment‑naïve patients with prostate cancer". Oncology Letters 23, no. 1 (2022): 6. https://doi.org/10.3892/ol.2021.13124